Abstract
Esophageal cancers are highly lethal neoplasms which are generally refractory to conventional multidisciplinary interventions. Recent elucidation of the mechanisms of esophageal carcinogenesis, as well as preclinical studies utilizing chromatin remodeling agents and inhibitors of oncogene signaling in conjunction with conventional chemotherapeutic agents provide new opportunities for the development of potentially efficacious molecular targeted therapies for these malignancies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 257-261 |
| Number of pages | 5 |
| Journal | Journal of surgical oncology |
| Volume | 92 |
| Issue number | 3 |
| DOIs | |
| State | Published - Dec 1 2005 |
| Externally published | Yes |
Keywords
- 5 Aza 2′deoxycytidine
- Clinical trial
- Depsipeptide FK228
- DNA demethylating agents
- Epigenetics
- Esophageal cancer
- HDAC inhibitors
- Mitogen activated protein kinase
ASJC Scopus subject areas
- Surgery
- Oncology
UN SDGs
This output contributes to the following Sustainable Development Goal(s)
